Abrocitinib Improves PROs Among Adolescents With Moderate to Severe Atopic Dermatitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of the European Academy of Dermatology and Venereology: JEADV
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes
J Eur Acad Dermatol Venereol 2021 Nov 07;[EPub Ahead of Print], MJ Cork, A McMichael, J Teng, H Valdez, R Rojo, G Chan, F Zhang, DE Myers, M DiBonaventuraFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.